The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

New therapies for ITP

Immune Thrombocytopenia, ITP, is an autoimmune bleeding disorder that is still treated with immunosuppressive drugs that cause serious side effects. Professor John Semple’s laboratory studies the pathophysiological mechanisms behind this disease and together with Dr. Drew Provan, London, UK, has recently published the newest ideas on pathological mechanisms and therapies for the treatment and management of ITP in eBioMedicine.

ITP is caused by the body's immune system attacking its own healthy platelets, which leads to an increased risk of various types of bleeding. ITP can occur in both children and adults and is somewhat more common among women. Many patients have few or only mild symptoms, but severe and life-threatening bleeding can occur e.g. intracranial hemorrhages.

– Patients with ITP have traditionally been treated with immunosuppressive drugs in the form of various types of corticosteroid preparations. But long-term use of corticosteroids can lead to serious side effects and patients literally hate this type of drug, says John Semple, research group leader at the Department of Laboratory Medicine.

On the contrary, new therapies such as the thrombopoietin receptor agonists (TPO-RA) are now being used routinely and are not immunosuppressive, but instead stimulate bone marrow megakaryocytes to produce more platelets. These new treatment options have few side effects and have changed the face of ITP treatment and management.

Semple's laboratory, a world leader in ITP research, is continuing to investigate the disease’s pathophysiological mechanisms in order to identify targets of therapy for this autoimmune condition.

– We are beginning to understand much more about the immunopathological mechanisms behind this disease, which has led to several potential new targeted therapies that offer better results and improved quality of life for patients with ITP. These aspects are explored in depth in our article now published in The The Lancet’s eBioMedicine
 

 

Publication

The article "Recent advances in the mechanisms and treatment of immune thrombocytopenia"
Drew Provan & John Semple
eBioMedicine 20 januari 2022

john semple. photo.

John Semple, Professor of Transfusion Medicine, Department of Laboratory Medicine, Lund University.

Link to profile in the LU Research Portal